Melissa Hughes MD
Assistant Professor, General Internal Medicine
801 Massachusetts Ave | (617) 414-4561hughesme@bu.edu
Sections
General Internal Medicine
Biography
I am the Clinical Director for Palliative Care at the Boston VA Brockton Campus, overseeing a 15-bed hospice unit as well as palliative care consults in the long-term care setting.
After graduating medical school from the Icahn School of Medicine at Mt. Sinai, I completed a General Surgery residency in Long Island NY followed by a Breast Surgical Oncology Fellowship in Buffalo NY. After practicing as a breast surgeon for several years, I then completed a Hospice and Palliative Care Fellowship in Buffalo NY and am now dedicating my practice to Hospice and Palliative Care. I am board certified in General Surgery and Hospice and Palliative Care.
I enjoy teaching the fellows and residents who rotate at the VA Brockton Campus who come from multiple programs throughout Boston. My clinical interests include complex pain and symptom management, end of life care, and bereavement support.
Websites
Education
MD, Mount Sinai School of Medicine
BA, Tufts University
Publications
Morganti S, Kim SE, Jin Q, Cha J, Zeigler JE, Newman AB, Kirkner GJ, Snow C, Zheng Y, Vincuilla J, Parker T, Buehler RM, Bychkovsky BL, Dibble KE, Sella T, Ruddy KJ, Rosenberg SM, Collins LC, Peppercorn J, Schapira L, Borges VF, Guzman-Arocho YD, Come SE, Warner E, Poorvu PD, Lambertini M, Curigliano G, Hughes ME, Mittendorf EA, King TA, Lin NU, Garber JE, Tayob N, Tolaney SM, Partridge AH, Lynce F. Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies. JNCI Cancer Spectr. 2026 Jul 07; 10(4). PMID: 42185079.
Published on 3/17/2026Corti C, Li T, Martin AR, Hughes ME, Parker T, Duporte TS, Curigliano G, King TA, Mittendorf EA, Lin NU, Tayob N, Tolaney SM. Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer. Breast. 2026 Jun; 87:104765. PMID: 41864057.
Published on 7/15/2025Priedigkeit N, Harrison B, Shue R, Hughes ME, Li Y, Lebrón-Torres A, Kirkner GJ, Spurr LF, Remolano MC, Strauss S, Files J, Feeney AM, Grant L, Mohammed-Abreu A, Garrido-Castro A, Barroso-Sousa R, Bychkovsky B, Nakhlis F, Bellon JR, King TA, Winer EP, Lindeman N, Johnson BE, Sholl L, Dillon D, Overmoyer B, Tolaney SM, Cherniack AD, Lin NU, Lynce F. Clinicogenomic Characterization of Inflammatory Breast Cancer. Clin Cancer Res. 2025 Jul 15; 31(14):3072-3083. PMID: 40378057.
Published on 4/14/2025Goel S, Jovanovic B, Chu X, Hughes M, Erick TK, Russo D, DiLullo M, Wrabel E, Jeselsohn R, Lin NU, Tayob N, Mittendorf E, Schnitt S, Tolaney SM. A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2025 Apr 14; 31(8):1427-1436. PMID: 39908010.
Published on 10/21/2024Rosenberg SM, Zheng Y, Santos K, Riley E, Meadows HW, Snow C, Hughes ME, Frank E, Lin NU, Partridge AH, Winer EP, Parsons HA. Patient-reported outcomes, and perceptions and knowledge about recurrence in women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):513-520. PMID: 39432162.
Published on 10/15/2024Jovanovic B, Church SE, Gorman KM, North K, Richardson ET, DiLullo M, Attaya V, Kasparian J, Mohammed-Abreu A, Kirkner G, Hughes ME, Lin NU, Mittendorf EA, Schnitt SJ, Tolaney SM, Goel S. Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies. Clin Cancer Res. 2024 Oct 15; 30(20):4768-4779. PMID: 39136550.
Published on 9/20/2024Erick TK, Lester SC, Garrido-Castro AC, Hughes M, Cunningham O, Lin NU, Mittendorf EA, Tolaney SM, Brock JE. Concordance of PD-L1 Expression in Metastatic Triple-negative Breast Cancer Between the 22C3 and E1L3N Antibodies Using Combined Positive Scoring. Appl Immunohistochem Mol Morphol. 2024 Oct 01; 32(9):417-424. PMID: 39351784.
Published on 6/4/2022Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, Patel A, Kirkner GJ, Hughes ME, Tolaney SM, Partridge AH, Krop IE, Knape C, Feger U, Marsico G, Howarth K, Winer EP, Lin NU, Parsons HA. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 2022 Aug 01; 40(22):2408-2419. PMID: 35658506.
Published on 10/29/2020Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020 Dec 20; 38(36):4274-4282. PMID: 33119476.
Published on 8/17/2020Yang DD, Buscariollo DL, Cronin AM, Weng S, Hughes ME, Bleicher RJ, Cohen AL, Javid SH, Edge SB, Moy B, Niland JC, Wolff AC, Hassett MJ, Punglia RS. Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. Radiat Oncol. 2020 Aug 17; 15(1):198. PMID: 32799886.